FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileBiomX Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
PHGE
BiomX Inc. Stock AnalysisComprehensive stock analysis for BiomX Inc. (PHGE) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPHGE
PHGE
BiomX Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
PHGE
  1. Home
  2. Stocks
  3. BiomX Inc.

BiomX Inc.

🇺🇸PHGE•AMEX

BiomX Inc.

🇺🇸PHGE•AMEX
Market cap
$1.88M

Your view on PHGE

Mkt Cap
$1.88M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About BiomX Inc.

Industry
Aerospace & Defense
Sector
Industrials
CEO
Jonathan Eitan Solomon MBA
Headquarters
22 Einstein Street, Ness Ziona, IL
Industry
Aerospace & Defense
Sector
Industrials
CEO
Jonathan Eitan Solomon MBA
Headquarters
22 Einstein Street, Ness Ziona, IL
Description

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria.

It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).

It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S.

aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients.

In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for BiomX Inc.. Starting points for BiomX Inc.: EPS -$44.04, beta 1.34 — an Aerospace & Defense name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for BiomX Inc.. Trailing twelve-month EPS for BiomX Inc. stands at -$44.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$38.00

average of analysts' targets

 

$38.00

Low $38.00

Median $38.00

High $38.00

 

Analyst Ratings

Buy5 ratings
  • Strong Buy0
  • Buy4
  • Hold1
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrSep 2026Next QtrDec 2026Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate−$703.00−$655.50−$58.50−$60.10
Low estimate−$703.00−$655.50−$58.50−$60.10
High estimate−$703.00−$655.50−$58.50−$60.10
No. of analysts1111
Year-ago EPS——−$221.90—
Growth——+73.6%—

Revenue Estimate

RevenueCurrent QtrSep 2026Next QtrDec 2026Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$332000.00$332000.00$23.55M$57.46M
Low estimate$332000.00$332000.00$23.55M$57.46M
High estimate$332000.00$332000.00$23.55M$57.46M
No. of analysts1111
Year-ago revenue——$0.00—
Growth————
Recent analyst actions15 rating and price-target changes, latest Mar 9, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for BiomX Inc.. BiomX Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold PHGE18 companies
Compare PHGE with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
BRTXBioRestorative Therapies, Inc.HealthcareBiotechnology$1.8M
DWTXDogwood Therapeutics, Inc.HealthcareBiotechnology$41.3M
EDSAEdesa Biotech, Inc.HealthcareBiotechnology$19.8M
ERNAErnexa Therapeutics Inc.HealthcareBiotechnology$2.7M
IMRNImmuron LimitedHealthcareBiotechnology$5.6M
MPLTMapLight Therapeutics, Inc.HealthcareBiotechnology$283.4M
More Aerospace & Defense companies
TickerTypeCompanySectorExchangeMkt cap
THLLYThales S.A.IndustrialsOTC$61.4B
TIKKTel-Instrument Electronics Corp.IndustrialsOTC$8.3M
TURATurbine Aviation, Inc.IndustrialsOTC$1
TXTTextron Inc.IndustrialsNYSE$14.0B
UITAUtilicraft Aerospace Industries, Inc.IndustrialsOTC$75,679
UMAVUAV Corp.IndustrialsOTC$15
VOYGVoyager Technologies, Inc.IndustrialsNYSE$1.3B
VSECVSE CorporationIndustrialsNASDAQ$5.2B
VSECUVSE CorporationIndustrialsNASDAQ$1.1B
VVXV2X, Inc.IndustrialsNYSE$2.5B
VWAVVisionWave Holdings, Inc.IndustrialsNASDAQ$2.5M
VWAVWVisionWave Holdings, Inc. WarrantIndustrialsNASDAQ$660,664
Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold BiomX Inc., and how their positions are changing. At a $1.9M market value, institutional positions materially move BiomX Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by BiomX Inc. executives and directors. Shares of BiomX Inc. have traded between $0.28 and $1.16 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for BiomX Inc.. Coverage tracks BiomX Inc. within Aerospace & Defense (Industrials). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of BiomX Inc.

PHGE AnalysisWeak
Past
1
Growth
2
Health
4
Profit
1
Value
1

News

Latest Market News